Repligen Corp (RGEN): R&D Expense
$54.18M
Year ended 2025-12-31
+7.2%
3-year compound annual growth
+21.8%
5-year compound annual growth
+25.2%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $54.18M | +25.4% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $43.20M | +1.1% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $42.72M | -2.8% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $43.94M | +28.2% | 2025-03-14, From 2022-01-01 |
| 2021-12-31 | $34.27M | +69.8% | 2024-11-18, From 2021-01-01 |
| 2020-12-31 | $20.18M | +3.8% | 2023-02-22, From 2020-01-01 |
| 2019-12-31 | $19.45M | +22.9% | 2022-02-17, From 2019-01-01 |
| 2018-12-31 | $15.82M | +82.4% | 2021-02-24, From 2018-01-01 |
| 2017-12-31 | $8.67M | +17.9% | 2020-02-26, From 2017-01-01 |
| 2016-12-31 | $7.36M | +28.1% | 2019-03-01, From 2016-01-01 |
| 2015-12-31 | $5.74M | +2.3% | 2018-02-22, From 2015-01-01 |
| 2014-12-31 | $5.61M | -23.6% | 2017-02-23, From 2014-01-01 |
| 2013-12-31 | $7.34M | -30.0% | 2016-02-25, From 2013-01-01 |
| 2012-12-31 | $10.49M | n/a | 2015-03-17, From 2012-01-01 |
| No annual figure between 2011-03-31 and 2012-12-31. | |||
| 2011-03-31 | $12.53M | -11.5% | 2013-03-15, From 2010-04-01 |
| 2010-03-31 | $14.16M | n/a | 2012-03-15, From 2009-04-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Repligen Corp (RGEN) | 2025-12-31 | $54.18M | +25.4% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $166.13M | -4.9% |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $4.76M | +162.7% |
| Novavax Inc (NVAX) | 2025-12-31 | $342.32M | -12.5% |
| Tarsus Pharmaceuticals, Inc. (TARS) | 2025-12-31 | $64.32M | +20.5% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $94.77M | -4.8% |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | $274.87M | +23.7% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $81.49M | +3.1% |
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $58.05M | +8.3% |
Compare RGEN, BCRX, ADMA, NVAX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗